Physician profile
Michael A Eckles
NPI 1548298466
$1,875.88
in general payments reported to CMS, 2019-2025
24 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $149 · 2021: $204 · 2022: $347 · 2023: $289 · 2024: $59.32 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $319.24 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| La Jolla Pharmaceutical Company | $248.40 | 2025 | Xacduro |
| Intuitive Surgical, INC. | $169.27 | 2025 | |
| Abbvie INC. | $151.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.37 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $138.66 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $115.55 | 2019-2023 | Fasenra |
| Allergan, INC. | $92.86 | 2019-2020 | |
| Insmed, INC. | $76.17 | 2022-2024 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $56.20 | 2020-2022 | |
| Genzyme Corporation | $47.89 | 2022-2025 | |
| Csl Behring | $35.64 | 2022-2024 | Kcentra |
| Inspire Medical Systems, INC. | $35.59 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $33.33 | 2019-2020 | |
| Genentech USA, INC. | $32.93 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.98 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $25.28 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.07 | 2019 | |
| Electromed, INC. | $21.12 | 2025 | Smartvest |
| Zoll Respicardia, INC. | $19.32 | 2023 | Remede System |
| Grifols USA, LLC | $17.41 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $15.66 | 2025 | Tyvaso |
| Abbott Laboratories | $15.07 | 2019 | |
| Lilly USA, LLC | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eckles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.